Figure 2.

Schematic representation of therapeutic strategies used to inhibit Androgen Receptor signaling in LAR TNBC patients. (A) Androgen are produced from cholesterol and CYP17-lyase inhibitors, like Abiraterone Acetate, Orteronel and Seviteronel, inhibit the conversion of cholesterol in androgen (1). On the contrary, the antiandrogens bicalutamide, enzalutamide, proxalutamide or seviteronel block androgen binding to androgen receptor (AR) (2). Different treatment strategies currently combining antiandrogen therapy, such as bicalutamide or enzalutamide with CDK4/6 inhibitor Abemaciclib, Palbociclib or Ribociclib (B), or with PI3K inhibitors Alpelisib or Raselisib (C), or immunotherapy with Ipilimumab or Nivolumab (D). Blue, light blue and orange arrows represent signaling activation, while red, blue, purple and green bars depict inhibition of target signals.